Navigation Links
Clinical Study: Dietary Supplement SagaPro Reduces Frequent Urination

REYKJAVIK, Iceland, July 6, 2012 /PRNewswire/ --

A recent clinical study on an Icelandic natural product has shown it to be effective against "nocturia" in those with low or diminished bladder capacity. Nocturia is the medical definition of the frequent need to urinate at night. This problem is common among men with prostate enlargement as well as people of all ages with an overactive bladder.


     (Photo: )

     (Photo: )

The product, SagaPro, which is made from the herb "Angelica archangelica", has been produced by SagaMedica in Iceland since 2005 and is very popular among nocturia sufferers. SagaPro has now been clinically studied and a peer-reviewed paper on the study will be published in the Scandinavian Journal of Urology and Nephrology.[1]

Increased nocturnal bladder volume

The study was performed in Iceland by Encode Ltd. and the whole process lasted one year. A total of sixty-nine participants, all of them men with "lower urinary tract symptoms", which includes prostate enlargement, were required to keep a detailed record of their nocturnal restroom trips as well as the volume of urine before and after a period of 8 weeks while they took either SagaPro or a placebo.

Findings showed significant results among different subgroups. In that regard, SagaPro had a pronounced effect on bladder volume and urinary frequency, two factors which affect the duration and quality of sleep.

"The findings were interesting in many ways. For instance, we saw that SagaPro had a significant and positive effect on those who had a low or diminished nocturnal bladder capacity. This knowledge will help us design other studies on SagaPro in the future" says Dr. Steinthor Sigurdsson, Ph.D. and a researcher at SagaMedica.

Not just a prostate product

The study sheds a light on how SagaPro can help those with prostate enlargement which affects a majority of men over 60. As SagaPro affects the bladder it indirectly helps men with prostate enlargement whose main complaint tends to be increased urinary frequency. The presence of a bladder-relaxing flavonoid in SagaPro had previously suggested the product worked through a bladder-related mechanism. Successful use by women and young people with enuresis (bed-wetting) also hinted at this and now the clinical study confirms that SagaPro affects the bladder, thereby helping sufferers of frequent urination.

Helps international marketing

SagaPro is currently marketed in over 200 retail outlets in the US and Canada. Perla Bjork Egilsdottir is SagaMedica's marketing manager: "The positive outcome of the clinical study will no doubt help us in further marketing SagaPro internationally. We expect the results to greatly increase our sales since the brand "SagaPro" has now been clinically verified for both safety and efficacy; not just the product's individual ingredients," she says.

Further studies

The clinical study on SagaPro is preceded by SagaMedica's considerable research on the Angelica herb. This is the 6th peer-reviewed paper the company's research team publishes since it was founded in 2000. The paper is entitled: "A parallel, randomised, double blind, placebo controlled study to investigate the effect of SagaPro on nocturia in men". Authors are the MD's Gudmundur Geirsson and Hrefna Gudmundsdottir and the biochemists Steinthor Sigurdsson, Perla B. Egilsdottir and professor Sigmundur Gudbjarnason.

Previous studies published by the company research team looked at the herb's potential benefits ranging from effects on a neurotransmitter to promote memory health to the potential uses of Angelica in the battle against cancer. Clinical studies on those properties are expected to follow in the future.

More information about SagaPro can be found on the company's website:

1. DOI NUMBER - 10.3109/00365599.2012.695390 [in press]

SOURCE SagaMedica
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Medical to Present at AACC Clinical Lab Expo 2012
2. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
3. Clinical Chemistry Market Report & Forecast (2012 - 2015): Global Analysis
4. Ulthera Launches New Aesthetic Clinical Indication - Treatment of the Decolletage - in Asia
5. Global Clinical Diagnostics Automation Industry
6. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
7. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
8. PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
9. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
10. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015   VolitionRx Limited (NYSE MKT: ... tests for a broad range of cancer types and other ... Micro Conference, which will be held December 1 - 3 in ... VolitionRx will be David Kratochvil , Chief Financial Officer ... Investor Relations. ® blood-based tests for colorectal ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology:
(Date:11/30/2015)... DC (PRWEB) , ... November ... ... Inc. (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: ... lessons learned from three innovative value-based care arrangements: Essentia Health and UCare, ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in the ... Matrix is a long-term resorbable surgical mesh intended to support and reinforce soft ...
(Date:11/30/2015)... Puerto Rico (PRWEB) , ... November 30, 2015 , ... ... active part of the San Juan Beauty Show held on November 8th and 9th ... was attended by media personalities, hair artists, renowned beauticians and top of the line ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... are pleased to announce their strategic partnership at the Radiological Society of ... Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation ...
(Date:11/30/2015)... ... 30, 2015 , ... World Patent Marketing , a ... household invention that provides an economical and easy way of gaining customized curtains. ... at 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
Breaking Medicine News(10 mins):